医学
催眠药
内科学
埃罗替尼
T790米
吉非替尼
肿瘤科
奥西默替尼
不利影响
临床终点
癌症
临床试验
表皮生长因子受体
作者
Makoto Nishio,Kazuto Nishio,Martin Reck,Edward B. Garon,Fumio Imamura,Tomoya Kawaguchi,Hiroyuki Yamaguchi,Satoshi Ikeda,Katsuya Hirano,Carla Visseren‐Grul,Matteo Ceccarelli,Sameera R. Wijayawardana,Annamaria H. Zimmermann,Tomoko Matsui,Sotaro Enatsu,Kazuhiko Nakagawa
标识
DOI:10.1016/j.jtocrr.2022.100303
摘要
Ramucirumab (RAM) plus erlotinib was found to have superior progression-free survival (PFS) versus placebo plus erlotinib in untreated EGFR-mutated metastatic NSCLC in the global phase 3 RELAY study. RELAY+ was an open-label, two-period, single-arm, exploratory study of RAM plus gefitinib (GEF; period 1) and RAM plus osimertinib (period 2) in East Asia (NCT02411448).Period 1 evaluated RAM (10 mg/kg) plus GEF (250 mg/d) in patients with untreated EGFR-mutated metastatic NSCLC. Period 2 evaluated RAM plus osimertinib (80 mg/d) in patients with disease progression who acquired T790M mutation in period 1. Exploratory end points included 1-year PFS rate (primary), other efficacy parameters, safety, and biomarker analyses of plasma (baseline, on-treatment, follow-up) using next-generation sequencing.From December 2017 to August 2018, a total of 82 patients were enrolled and started treatment (period 1, RAM + GEF). The 1-year PFS rate was 62.9% (95% confidence interval: 50.3-73.1). Treatment-emergent adverse events of grade three or higher were reported with RAM plus GEF in 60 of 82 patients (73.2%; five patients [6.1%] grade four). There were two deaths owing to adverse events that occurred (acute cardiac failure, congestive cardiac failure). T790M rate at disease progression in plasma was 81.0% (13 of 16 patients).RELAY+ was found to have a favorable benefit-risk profile for RAM plus GEF in first-line treatment of East Asian patients with EGFR-mutated NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI